Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)
Piedra, Aida (Universitat Autònoma de Barcelona)
Guinart Cuadra, Albert (Institut de Recerca Sant Pau)
Martinez-Recio, Sergio (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Mulet Gual, Maria (Institut de Recerca Sant Pau)
Zamora, Carlos (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Osuna Gómez, Rubén (Institut de Recerca Sant Pau)
Cantó, Elisabet (Institut de Recerca Sant Pau)
Ortiz, M. Àngels (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Alejandre, Jose (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Barba Joaquin, Andrés (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Sanz-Beltran, Judit (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Serra, Jorgina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya))
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid))
Diz Taín, Pilar (Complejo Asistencial Universitario de León)
Moreno Vega, Alberto Luis (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Callejo, A. (Astrazeneca Farmacéutica Spain S.A.)
Vidal, Silvia (Institut de Recerca Sant Pau)
Majem, Margarita (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))

Data:	2026
Resum:	Introduction: Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum250 based chemotherapy for extensive-stage small cell lung cancer (ES-SCLC), long-term survival remains limited. There is currently no available predictive biomarker to identify which patients would benefit most from this treatment. We hypothesized that pre253 treatment PD-L1 expression on circulating immune cells might predict survival outcomes and toxicity. Material and methods: This prospective, multi-center observational study included patients with untreated ES257 SCLC treated with first-line durvalumab plus platinum-based chemotherapy. The percentages of circulating PD-L1+ immune cells at baseline were analysed by flow cytometry to assess their association with survival outcomes and the development of immune-related adverse events (irAEs). Results: Among 41 patients with ES-SCLC, 65. 9% were male, 73. 2% had an ECOG-PS 1, 9. 8% had central nervous system (CNS) metastases and 31. 7% had liver metastases. Sixteen patients (39%) experienced irAEs. Median PFS was longer in patients with high percentages of circulating PD-L1 265 + monocytes compared to those with low percentages: 266 8. 97 months (95% CI NR to NR) vs. 5. 97 months (95% CI 4. 65 to 7. 28), p=0. 007. There was a trend toward longer median OS in patients with ES-SCLC and high percentages of circulating PD-L1 268 + monocytes versus low percentages: NR (95% CI NR-NR) vs. 9. 13 months (95% CI 6. 34 to 11. 92), p=0. 092. Patients with higher circulating PD-L1+ neutrophils correlated with the development of irAES (p=0. 007). Conclusions: Our results showed a statistically significant longer PFS in patients with ES-SCLC and high percentages of circulating PD-L1 274 + monocytes. This suggests PD-L1 expression on monocytes might be established as a predictive biomarker for patients with ES-SCLC treated with upfront chemo-immunotherapy.
Drets:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Llengua:	Anglès
Document:	Article ; recerca ; Versió acceptada per publicar
Matèria:	Predictive biomarker ; Extensive stage small-cell lung cancer (ES-SCLC) ; Circulating immune cells ; Circulating PD-L1+ monocytes ; circulating PD-L1+ 283 neutrophils ; Immunotherapy
Publicat a:	Journal of translational medicine, 2026 , ISSN 1479-5876

Disponible a partir de: 2099-01-01 43 p, 940.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats